DE69232649D1 - Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b - Google Patents

Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b

Info

Publication number
DE69232649D1
DE69232649D1 DE69232649T DE69232649T DE69232649D1 DE 69232649 D1 DE69232649 D1 DE 69232649D1 DE 69232649 T DE69232649 T DE 69232649T DE 69232649 T DE69232649 T DE 69232649T DE 69232649 D1 DE69232649 D1 DE 69232649D1
Authority
DE
Germany
Prior art keywords
thiacytidine
deoxy
fluoro
treating hepatitis
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232649T
Other languages
English (en)
Other versions
DE69232649T2 (de
Inventor
Dennis C Liotta
Raymond F Schinazi
Woo-Baeg Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919104741A external-priority patent/GB9104741D0/en
Priority claimed from GB919109505A external-priority patent/GB9109505D0/en
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of DE69232649D1 publication Critical patent/DE69232649D1/de
Publication of DE69232649T2 publication Critical patent/DE69232649T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69232649T 1991-03-06 1992-03-05 Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b Expired - Lifetime DE69232649T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919104741A GB9104741D0 (en) 1991-03-06 1991-03-06 Therapeutic nucleosides
GB919109505A GB9109505D0 (en) 1991-05-02 1991-05-02 Therapeutic nucleosides
PCT/GB1992/000388 WO1992015308A1 (en) 1991-03-06 1992-03-05 Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b

Publications (2)

Publication Number Publication Date
DE69232649D1 true DE69232649D1 (de) 2002-07-25
DE69232649T2 DE69232649T2 (de) 2002-11-28

Family

ID=26298535

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69232649T Expired - Lifetime DE69232649T2 (de) 1991-03-06 1992-03-05 Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
DE69233693T Expired - Lifetime DE69233693T2 (de) 1991-03-06 1992-03-05 Salze und Amide von (-) cis 5-Fluoro-2'-deoxy-3'-thiacytidine geeignet für die Behandlung von Hepatitis B

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69233693T Expired - Lifetime DE69233693T2 (de) 1991-03-06 1992-03-05 Salze und Amide von (-) cis 5-Fluoro-2'-deoxy-3'-thiacytidine geeignet für die Behandlung von Hepatitis B

Country Status (21)

Country Link
EP (3) EP0574487B1 (de)
JP (5) JP3479068B2 (de)
KR (1) KR100270806B1 (de)
AT (2) ATE361293T1 (de)
AU (1) AU662130B2 (de)
CA (1) CA2105486C (de)
CZ (1) CZ282747B6 (de)
DE (2) DE69232649T2 (de)
DK (2) DK0574487T3 (de)
ES (2) ES2286072T3 (de)
HU (1) HUT64844A (de)
IE (1) IE920701A1 (de)
IL (1) IL101144A (de)
MX (1) MX9203213A (de)
NZ (1) NZ264621A (de)
PT (1) PT100198B (de)
RU (1) RU2116789C1 (de)
SK (1) SK279542B6 (de)
TW (1) TW201268B (de)
UA (1) UA54364C2 (de)
WO (1) WO1992015308A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2196004T3 (es) * 1989-02-08 2003-12-16 Iaf Biochem Int Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales.
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ241625A (en) 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
PT100198B (pt) * 1991-03-06 2000-03-31 Univ Emory Utilizacao de nucleosido oxatiolano para a preparacao de composicoes para fins terapeuticos
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
WO1996040164A1 (en) 1995-06-07 1996-12-19 Emory University Nucleosides with anti-hepatitis b virus activity
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
EP0970078B1 (de) * 1997-03-19 2004-05-19 Emory University Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
AU5475799A (en) 1998-08-10 2000-03-06 Centre National De La Recherche Scientifique Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis
CA2340214C (en) 1998-08-12 2007-10-30 Triangle Pharmaceuticals, Inc. Method of manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
CA2410579C (en) 2000-05-26 2010-04-20 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1387850A2 (de) 2001-05-18 2004-02-11 Rakesh Kumar Antivirale nukleoside
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
HUE027522T2 (en) 2002-09-13 2016-11-28 Novartis Ag ß-L-2'-Deoxynucleosides for treatment of resistant HBV strains and for combination therapies
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
AU2009267052B2 (en) 2008-06-30 2013-07-11 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
WO2013004658A1 (en) * 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
NZ241625A (en) * 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
PT100198B (pt) * 1991-03-06 2000-03-31 Univ Emory Utilizacao de nucleosido oxatiolano para a preparacao de composicoes para fins terapeuticos

Also Published As

Publication number Publication date
IL101144A (en) 1996-09-12
SK279542B6 (sk) 1998-12-02
WO1992015308A1 (en) 1992-09-17
ES2286072T3 (es) 2007-12-01
HUT64844A (en) 1994-03-28
JP2007246536A (ja) 2007-09-27
IE920701A1 (en) 1992-09-09
AU1367692A (en) 1992-10-06
EP1808434A2 (de) 2007-07-18
ES2179040T3 (es) 2003-01-16
UA54364C2 (uk) 2003-03-17
KR100270806B1 (ko) 2000-11-01
IE20040402A1 (en) 2007-10-17
MX9203213A (es) 1992-07-01
EP1808434A3 (de) 2008-04-02
IL101144A0 (en) 1992-11-15
DE69232649T2 (de) 2002-11-28
JP4891435B2 (ja) 2012-03-07
DE69233693T2 (de) 2008-01-24
HU9302493D0 (en) 1993-11-29
CA2105486A1 (en) 1992-09-07
RU2116789C1 (ru) 1998-08-10
CA2105486C (en) 2003-10-28
JP4399478B2 (ja) 2010-01-13
EP1142891B1 (de) 2007-05-02
NZ264621A (en) 1997-09-22
JP3987335B2 (ja) 2007-10-10
JP2002220388A (ja) 2002-08-09
SK95093A3 (en) 1994-04-06
DE69233693D1 (de) 2007-06-14
JP2010013466A (ja) 2010-01-21
CZ282747B6 (cs) 1997-09-17
EP0574487B1 (de) 2002-06-19
TW201268B (de) 1993-03-01
PT100198A (pt) 1993-05-31
EP1142891A1 (de) 2001-10-10
AU662130B2 (en) 1995-08-24
ATE219366T1 (de) 2002-07-15
EP0574487A1 (de) 1993-12-22
ATE361293T1 (de) 2007-05-15
DK1142891T3 (da) 2007-08-27
JP3479068B2 (ja) 2003-12-15
CZ183593A3 (en) 1994-04-13
PT100198B (pt) 2000-03-31
DK0574487T3 (da) 2002-10-14
JP2011102308A (ja) 2011-05-26
JPH06505725A (ja) 1994-06-30

Similar Documents

Publication Publication Date Title
DE69232649T2 (de) Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
ITMI931522A0 (it) Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
IL101836A0 (en) Pharmaceutical compositions containing 1,3-oxathiolane nucleoside derivatives
RU93043875A (ru) 1-(2-гидроксиметил)-1,3-оксатиолан-5-ил)-5-фторцитозин и способ лечения
DK224286A (da) 2',3'-dideoxy-nucleosider
MD950086A (ro) Utilizare a analogilor nucleozidici ai 1,3-oxatiolanei in tratamentul hepatitei B Use of 1,3-oxathiolan nucleoside analogues in the treatment of hepatitis B
DE69535758D1 (de) Lipid-analoge zur behandlung von viralen infektionen
DE3773892D1 (de) Medizinische verwendung von nukleosiden.
MY127808A (en) Use of dideoxy nucleoside analogues in the treatment of viral infections
EA199900843A1 (ru) Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
NO931246D0 (no) Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv)
PT87004A (pt) Process for the preparation of compositions for the treatment of viral infections and composites 3'-azide-2',3'-didesoxy-in osine and 3'-fluoro-2',3'-didesoxyguanosine
MY137298A (en) Therapeutic nucleosides
RU93058325A (ru) Применение производных 1,3-оксатиолана для получения лекарственных препаратов для лечения или профилактики вирусной инфекции гепатита в, применение производных 1,3 - оксатиолана для лечения инфекций гепатита в, способ лечения гепатита в
MY113560A (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
YU221289A (en) Antivirus compounds
GR920100326A (el) Ενώσεις και μέ?οδοι αναστολής του HIV και των σχετικών ιών.
ATE100318T1 (de) Verwendung von chinolyl- und isochinolyloxazol-2- onen zur herstellung eines arzneimittels zur verhinderung der ansteckungsfaehigkeit von mit glykoproteinen umhuellten viren.
ZA932271B (en) Compositions for the treatment of infection and disease caused by hepatitis B virus (HBV)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition